Literature DB >> 15037406

Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection.

Flávio Garcia Oliveira1, Vicente G Abdelmassih, Michael P Diamond, Dimitri Dozortsev, Nilson R Melo, Roger Abdelmassih.   

Abstract

OBJECTIVE: To further evaluate the effects of intramural and subserosal uterine fibroids on the outcome of IVF-ET, when there is no compression of the endometrial cavity.
DESIGN: Retrospective, matched-control study from January 2000 to October 2001.
SETTING: Private IVF center. PATIENT(S): Two hundred forty-five women with subserosal and/or intramural fibroids that did not compress the uterine cavity (fibroid group) and 245 women with no evidence of fibroids anywhere in the uterus (control group). INTERVENTION(S): In vitro fertilization-intracytoplasmic sperm injection (IVF-ICSI) cycles. MAIN OUTCOME MEASURE(S): The type of fibroid (intramural, subserosal), number, size (cm), and location of intramural leiomyomas (fundal, corpus) were recorded. Outcomes of IVF-ICSI cycles were compared between the two groups. RESULT(S): There was no correlation between location and number of uterine fibroids and the outcomes of IVF-ICSI. Patients with subserosal or intramural fibroids <4 cm had IVF-ICSI outcomes (pregnancy, implantation, and abortion rates) similar to those of controls. Patients with intramural fibroids >4.0 cm had lower pregnancy rates than patients with intramural fibroids <or=4.0 cm. There were no statistical differences related to delivery rates (31.5% vs. 32%, respectively) between all patients with fibroids and controls. Premature delivery rates for singleton gestations were 10% vs. 8%, respectively, in all patients with fibroid and controls. CONCLUSION(S): Patients having subserosal or intramural leiomyomas of <4 cm not encroaching on the uterine cavity have IVF-ICSI outcomes comparable to those of patients without such leiomyomas. Therefore, they might not require myomectomy before being scheduled for assisted reproduction cycles. However, we recommend caution for patients with fibroids >4 cm and that such patients be submitted to treatment before they are enrolled in IVF-ICSI cycles. Whether or not women with fibroids > 4 cm would benefit from fibroid treatment remains to be determined.

Entities:  

Mesh:

Year:  2004        PMID: 15037406     DOI: 10.1016/j.fertnstert.2003.08.034

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  22 in total

1.  Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility.

Authors:  Aaron K Styer; Susan Jin; Dan Liu; Baisong Wang; Alex J Polotsky; Mindy S Christianson; Wendy Vitek; Lawrence Engmann; Karl Hansen; Robert Wild; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Alicia Christy; Michael P Diamond; Esther Eisenberg; Heping Zhang; Nanette Santoro
Journal:  Fertil Steril       Date:  2017-01-12       Impact factor: 7.329

2.  Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility.

Authors:  Hao Huang; Hongying Kuang; Fangbai Sun; Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter R Casson; Gregory M Christman; Karl R Hansen; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2019-03-27       Impact factor: 7.329

3.  Uterine leiomyomata and fecundability in the Right from the Start study.

Authors:  Gayle Johnson; Richard F MacLehose; Donna D Baird; Shannon K Laughlin-Tommaso; Katherine E Hartmann
Journal:  Hum Reprod       Date:  2012-07-18       Impact factor: 6.918

Review 4.  The impact of uterine leiomyomas on reproductive outcomes.

Authors:  H Cook; M Ezzati; J H Segars; K McCarthy
Journal:  Minerva Ginecol       Date:  2010-06

5.  Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity.

Authors:  Leo F Doherty; Hugh S Taylor
Journal:  Fertil Steril       Date:  2015-01-14       Impact factor: 7.329

Review 6.  Is Myomectomy Prior to Assisted Reproductive Technology Cost Effective in Women with Intramural Fibroids?

Authors:  Mary Ojo-Carons; Sunni L Mumford; Alicia Y Armstrong; Alan H DeCherney; Kate Devine
Journal:  Gynecol Obstet Invest       Date:  2016-03-19       Impact factor: 2.031

Review 7.  Management of uterine fibroids in the patient pursuing assisted reproductive technologies.

Authors:  Mohammad Ezzati; John M Norian; James H Segars
Journal:  Womens Health (Lond)       Date:  2009-07

Review 8.  Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances.

Authors:  Gary Levy; Micah J Hill; Stephanie Beall; Shvetha M Zarek; James H Segars; William H Catherino
Journal:  J Assist Reprod Genet       Date:  2012-05-15       Impact factor: 3.412

9.  Effects of noncavity-distorting fibroids on endometrial gene expression and function.

Authors:  Lusine Aghajanova; Sahar Houshdaran; Juan C Irwin; Linda C Giudice
Journal:  Biol Reprod       Date:  2017-10-01       Impact factor: 4.285

10.  Fibroids, infertility and laparoscopic myomectomy.

Authors:  Pankaj Desai; Purvi Patel
Journal:  J Gynecol Endosc Surg       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.